S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.28 (-2.24%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.74 (-1.68%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.28 (-2.24%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.74 (-1.68%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.28 (-2.24%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.74 (-1.68%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.28 (-2.24%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.74 (-1.68%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)

Hims & Hers Health (HIMS) Stock Price, News & Analysis

$8.80
+0.16 (+1.85%)
(As of 05:32 PM ET)
Compare
Today's Range
$8.64
$8.88
50-Day Range
$5.76
$8.90
52-Week Range
$5.65
$12.34
Volume
1.49 million shs
Average Volume
2.96 million shs
Market Capitalization
$1.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.08

Hims & Hers Health MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
37.3% Upside
$12.08 Price Target
Short Interest
Bearish
12.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.12mentions of Hims & Hers Health in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$785,410 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.13) to ($0.06) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

383rd out of 945 stocks

Offices & Clinics Of Medical Doctors Industry

2nd out of 6 stocks


HIMS stock logo

About Hims & Hers Health Stock (NYSE:HIMS)

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.

HIMS Stock Price History

HIMS Stock News Headlines

Ozempic vs. Mounjaro:: Battle of the bulge (HIMS)
The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs, led by the popularity of Ozempic. Celebrity usage
Hims & Hers earnings highlight expanded personalized treatments
E-health and wellness platform operator Hims & Hers Inc. reported a stellar quarter of growth that highlighted its expanded line of personalized products
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Is Hims & Hers Stock a Buy Now?
Hims & Hers Health
Hims & Hers: The Most Undervalued Small Cap Stock I See
Hims Online Therapy Review 2023
Hims & Hers Health's Outlook Starts to Firm Up
See More Headlines
Receive HIMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
12/11/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/26/2024

Industry, Sector and Symbol

Industry
Offices & clinics of medical doctors
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
651
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.08
High Stock Price Target
$18.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+38.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$-65,680,000.00
Pretax Margin
-4.39%

Debt

Sales & Book Value

Annual Sales
$526.92 million
Book Value
$1.50 per share

Miscellaneous

Free Float
144,940,000
Market Cap
$1.85 billion
Optionable
Optionable
Beta
0.78
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Andrew  DudumMr. Andrew Dudum (Age 34)
    Co-Founder, Chairman & CEO
    Comp: $1.7M
  • Mr. Yemi Okupe (Age 37)
    Chief Financial Officer
    Comp: $804.05k
  • Ms. Melissa  BairdMs. Melissa Baird (Age 45)
    Chief Operating Officer
    Comp: $917.67k
  • Ms. Irene A. Becklund (Age 38)
    Senior VP, Controller & Principal Accounting Officer
    Comp: $361.12k
  • Ms. Soleil Teubner Boughton (Age 44)
    Chief Legal Officer & Corporate Secretary
    Comp: $782.66k
  • Mr. Mike Chi (Age 43)
    Chief Marketing Officer
    Comp: $514.77k
  • Dr. Patrick Carroll M.D. (Age 65)
    Chief Medical Officer, Member of Medical Advisory Board & Director
    Comp: $27.03k
  • Ms. Khobi Brooklyn
    Chief Communications Officer
  • Ms. Amee Parekh
    Senior Vice President of Human Resources
  • Dr. Peter Stahl M.D.
    Senior VP & Member of Medical Advisory Board














HIMS Stock Analysis - Frequently Asked Questions

Should I buy or sell Hims & Hers Health stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HIMS shares.
View HIMS analyst ratings
or view top-rated stocks.

What is Hims & Hers Health's stock price target for 2024?

9 brokers have issued twelve-month price objectives for Hims & Hers Health's shares. Their HIMS share price targets range from $9.00 to $18.00. On average, they predict the company's share price to reach $12.08 in the next year. This suggests a possible upside of 37.3% from the stock's current price.
View analysts price targets for HIMS
or view top-rated stocks among Wall Street analysts.

How have HIMS shares performed in 2023?

Hims & Hers Health's stock was trading at $6.41 at the start of the year. Since then, HIMS stock has increased by 37.3% and is now trading at $8.80.
View the best growth stocks for 2023 here
.

When is Hims & Hers Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our HIMS earnings forecast
.

How were Hims & Hers Health's earnings last quarter?

Hims & Hers Health, Inc. (NYSE:HIMS) posted its quarterly earnings data on Monday, November, 6th. The company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by $0.01. The business had revenue of $226.70 million for the quarter, compared to analyst estimates of $220.08 million. Hims & Hers Health had a negative net margin of 4.50% and a negative trailing twelve-month return on equity of 11.22%. Hims & Hers Health's revenue for the quarter was up 56.6% compared to the same quarter last year. During the same period last year, the firm earned ($0.09) EPS.

Who are Hims & Hers Health's major shareholders?

Hims & Hers Health's stock is owned by a number of institutional and retail investors. Top institutional investors include Institutional Venture Management XVI LLC (3.66%), Institutional Venture Management XV LLC (3.66%), Jupiter Asset Management Ltd. (0.69%), Charles Schwab Investment Management Inc. (0.60%), Northern Trust Corp (0.55%) and Federated Hermes Inc. (0.49%). Insiders that own company stock include Alex Bard, Andrew Dudum, David B Wells, David B Wells, Irene Becklund, Jack Abraham, Jules A Maltz, Lynne Chou O'keefe, Melissa Baird, Oluyemi Okupe, Patrick Harrison Carroll, Soleil Boughton and Spencer Lee.
View institutional ownership trends
.

How do I buy shares of Hims & Hers Health?

Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:HIMS) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -